Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Tretinoin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA known ✓ | P19793 | 5/20 | 1.00 |
| ▸ | RARA known ✓ | P10276 | 4/20 | 1.00 |
| ▸ | RARB known ✓ | P10826 | 4/20 | 1.00 |
| ▸ | RARG known ✓ | P13631 | 4/20 | 1.00 |
| ▸ | RXRB known ✓ | P28702 | 2/20 | 1.00 |
| ▸ | RXRG known ✓ | P48443 | 2/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 12/20 | 1.00 |
| ▸ | MAPT | P10636 | 9/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 6/20 | 1.00 |
| ▸ | PTGS1 | P23219 | 4/20 | 1.00 |
| ▸ | APP | P05067 | 4/20 | 1.00 |
| ▸ | SNCA | P37840 | 4/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 3/20 | 1.00 |
| ▸ | ALOX15 | P16050 | 3/20 | 1.00 |
| ▸ | RORC | P51449 | 2/20 | 1.00 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 1.00 |
| ▸ | HTR2B | P41595 | 2/20 | 1.00 |
| ▸ | BLM | P54132 | 2/20 | 1.00 |
| ▸ | HIF1A | Q16665 | 2/20 | 1.00 |
| ▸ | DRD3 | P35462 | 2/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tretinoin SCHEMBL3146 | 1.00 | ALDH1A1 (1.00) | ALDH1A1MAPTCYP3A4RXRARARA | |
| Isotretinoin SCHEMBL9123793 | 1.00 | ALDH1A1 (1.00) | ALDH1A1MAPTCYP3A4RXRARARA | |
| Tretinoin SCHEMBL8399912 | 1.00 | ALDH1A1 (1.00) | ALDH1A1MAPTCYP3A4RXRARARA | |
| Tretinoin SCHEMBL7846921 | 1.00 | ALDH1A1 (1.00) | ALDH1A1MAPTCYP3A4RXRARARA | |
| Tretinoin SCHEMBL24982760 | 1.00 | ALDH1A1 (1.00) | ALDH1A1MAPTCYP3A4RXRARARA | |
| Isotretinoin SCHEMBL38299 | 1.00 | ALDH1A1 (1.00) | ALDH1A1MAPTCYP3A4RXRARARA | |
| Tretinoin SCHEMBL24982761 | 1.00 | ALDH1A1 (1.00) | ALDH1A1MAPTCYP3A4RXRARARA | |
| Alitretinoin SCHEMBL5331051 | 1.00 | ALDH1A1 (1.00) | ALDH1A1MAPTCYP3A4RXRARARA | |
| Tretinoin SCHEMBL18667 | 1.00 | ALDH1A1 (1.00) | ALDH1A1MAPTCYP3A4RXRARARA | |
| Isotretinoin SCHEMBL20603086 | 1.00 | ALDH1A1 (1.00) | ALDH1A1MAPTCYP3A4RXRARARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 180 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3370737-B1 | ANTI-AGING COMPOSITIONS AND METHODS FOR USING SAME | PRESCIENT PHARMA LLC (US) | 2021-09-22 | — | — | EP | claimed |
| US-20200046746-A1 | ANTI-AGING COMPOSITIONS AND METHODS FOR USING SAME | LISPIRO LLC | 2020-02-13 | — | — | US | claimed |
| US-10363263-B2 | Anti-aging compositions and methods for using same | PRESCIENT PHARMA, LLC (US) | 2019-07-30 | — | — | US | claimed |
| US-20180318324-A1 | ANTI-AGING COMPOSITIONS AND METHODS FOR USING SAME | PRESCIENT PHARMA LLC (US) | 2018-11-08 | — | — | US | claimed |
| EP-3370737-A1 | ANTI-AGING COMPOSITIONS AND METHODS FOR USING SAME | Prescient Pharma LLC (US) | 2018-09-12 | — | — | EP | claimed |
| US-20170182075-A1 | ANTI-AGING COMPOSITIONS AND METHODS FOR USING SAME | REED, KENNETH M. | 2017-06-29 | — | — | US | claimed |
| WO-2017079463-A1 | ANTI-AGING COMPOSITIONS AND METHODS FOR USING SAME | PRESCIENT PHARMA LLC (US) | 2017-05-11 | — | — | WO | claimed |
| CN-105143445-A | Maturation of hepatocyte-like cells derived from human pluripotent stem cells | TAKARA BIO EUROP AB | 2015-12-09 | — | — | CN | claimed |
| CN-101774954-B | Method for preparing all-trans tretinoin | CHONGQING HUABANG SHENGKAI PHARMACEUTICAL CO LTD | 2013-08-07 | — | — | CN | claimed |
| US-7964639-B2 | Reducing toxicity; esterification; side effect reduction; skin disorders; wrinkle resistance; anticancer agents | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2011-06-21 | — | — | US | claimed |
| US-20050002879-A1 | External skin compositions | KAO CORPORATION (JP) | 2005-01-06 | — | — | US | claimed |
| US-20040167215-A1 | Modified retinoid compounds and their uses | WISCONSIN ALUMNI RESEARCH FOUNDATION | 2004-08-26 | — | — | US | claimed |
| WO-2004064743-A2 | MODIFIED RETINOID COMPOUNDS AND THEIR USES | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2004-08-05 | — | — | WO | claimed |
| WO-2004065358-A2 | METHOD OF REDUCING TOXICITY OF RETINOIDS | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2004-08-05 | — | — | WO | claimed |
| EP-0824348-B1 | TREATMENT OF PSORIASIS WITH 11-CIS-RETINOIC ACID | BRAIMAN MARK S (US) | 2002-09-11 | — | — | EP | claimed |
| EP-0824348-A1 | TREATMENT OF PSORIASIS WITH 11-CIS-RETINOIC ACID | BRAIMAN, Mark S. (US) | 1998-02-25 | — | — | EP | claimed |
| US-5719195-A | Treatment of psoriasis with 11-cis-retinoic acid | 4 THOUGHT TECHNOLOGIES (US) | 1998-02-17 | — | — | US | claimed |
| EP-0625045-A4 | METHODS OF TREATING INFLAMMATORY DERMATOSES. | KLIGMAN ALBERT M (US) | 1995-01-18 | — | — | EP | claimed |
| EP-0625045-A1 | METHODS OF TREATING INFLAMMATORY DERMATOSES | Kligman, Albert M. (US) | 1994-11-23 | — | — | EP | claimed |
| WO-1993015740-A1 | METHODS OF TREATING INFLAMMATORY DERMATOSES | KLIGMAN ALBERT M (US) | 1993-08-19 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040167215-A1 | Modified retinoid compounds and their uses | RARB, RARA, RARG | RXRA 5/4885RARA 2/4885RARB 1/4885 |
| US-20200046746-A1 | ANTI-AGING COMPOSITIONS AND METHODS FOR USING SAME | GLA, LIMS1, GLB1 | RXRA 3824/4885RARA 4008/4885RARB 4243/4885 |
| US-10363263-B2 | Anti-aging compositions and methods for using same | GLA, LIMS1, GLB1 | RXRA 3824/4885RARA 4008/4885RARB 4243/4885 |
| US-20180318324-A1 | ANTI-AGING COMPOSITIONS AND METHODS FOR USING SAME | GLA, LIMS1, GLB1 | RXRA 3824/4885RARA 4008/4885RARB 4243/4885 |
| US-20170182075-A1 | ANTI-AGING COMPOSITIONS AND METHODS FOR USING SAME | GLA, LIMS1, GLB1 | RXRA 3824/4885RARA 4008/4885RARB 4243/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.